--- title: "Citigroup Reiterates \"Neutral\" Rating for GSK (NYSE:GSK)" type: "News" locale: "en" url: "https://longbridge.com/en/news/293754519.md" description: "Citigroup reaffirmed a 'neutral' rating on GSK shares. Other analysts also adjusted ratings: Deutsche Bank held, Weiss downgraded slightly, Wall Street Zen upgraded to buy, HSBC upgraded to hold, and RBC reiterated outperform. The consensus rating is 'Hold' with a target price of $53.00. Key developments include FDA approval for lung cancer drug Jideytro, validating the Nuvalent acquisition, and expected double-digit growth in Specialty Medicines." datetime: "2026-07-24T12:06:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293754519.md) - [en](https://longbridge.com/en/news/293754519.md) - [zh-HK](https://longbridge.com/zh-HK/news/293754519.md) generator: "portal-rs" --- # Citigroup Reiterates "Neutral" Rating for GSK (NYSE:GSK) GSK (NYSE:GSK - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at Citigroup in a report issued on Friday,Benzinga reports. - MarketBeat Week in Review – 06/08 - 06/12 A number of other analysts have also weighed in on GSK. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of GSK in a research note on Thursday, July 9th. Weiss Ratings downgraded shares of GSK from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, June 11th. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Saturday, June 27th. HSBC raised GSK from a "reduce" rating to a "hold" rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada reiterated an "outperform" rating on shares of GSK in a report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, GSK currently has an average rating of "Hold" and a consensus target price of $53.00. **Get Our Latest Stock Analysis on GSK** ## GSK Stock Performance - Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion NYSE:GSK opened at $50.78 on Friday. The company has a fifty day simple moving average of $51.55 and a two-hundred day simple moving average of $53.41. The company has a market cap of $102.71 billion, a price-to-earnings ratio of 13.20, a price-to-earnings-growth ratio of 3.23 and a beta of 0.35. The company has a quick ratio of 0.52, a current ratio of 0.79 and a debt-to-equity ratio of 0.80. GSK has a 52 week low of $36.75 and a 52 week high of $61.69. ## Institutional Inflows and Outflows A number of institutional investors have recently bought and sold shares of GSK. First Horizon Corp boosted its stake in shares of GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company's stock worth $26,000 after buying an additional 236 shares during the period. Elyxium Wealth LLC acquired a new position in GSK in the 4th quarter valued at about $30,000. Triumph Capital Management purchased a new stake in GSK during the 3rd quarter valued at approximately $40,000. Coston McIsaac & Partners lifted its position in GSK by 17.3% during the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company's stock worth $68,000 after acquiring an additional 206 shares during the period. Finally, Bogart Wealth LLC lifted its position in GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company's stock worth $83,000 after acquiring an additional 200 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds. ## Key Headlines Impacting GSK - The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat Here are the key news stories impacting GSK this week: - Positive Sentiment: GSK received FDA approval for Jideytro, its first lung cancer treatment, ahead of the original review deadline, supporting its precision oncology expansion. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer - Positive Sentiment: The approval strengthens the case for GSK’s recent Nuvalent acquisition, with multiple reports highlighting that the deal is already delivering a commercial win in oncology. GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet - Positive Sentiment: GSK also said its Specialty Medicines unit is expected to post double-digit growth, driven by newer HIV, respiratory/inflammation, and oncology drugs, which could help offset pressure from older products. Will GSK's Specialty Medicines Boost Q2 Revenue Growth? - Neutral Sentiment: Separately, GSK is also seeking an EMA label update for Bexsero and reported positive phase II data for Jemperli in rectal cancer, but these updates are earlier-stage and less immediately material than the FDA approval. GSK LSE: GSK Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance ## About GSK (Get Free Report) GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines. GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing. ## Recommended Stories - Five stocks we like better than GSK - Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? - Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction - Premium Retail’s Stress Test Is Separating Winners From Losers - D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in GSK Right Now? Before you consider GSK, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list. While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [NUVL.US](https://longbridge.com/en/quote/NUVL.US.md) ## Related News & Research - [GSK to advance mRNA flu vaccine to late-stage trial](https://longbridge.com/en/news/297605972.md) - [GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors](https://longbridge.com/en/news/297654888.md) - [Jemperli accepted for priority review by US FDA](https://longbridge.com/en/news/298022487.md) - [Deutsche Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)](https://longbridge.com/en/news/297776249.md) - [Daiwa Upgrades HUTCHMED to Buy in One Go, Raises TP to HKD28.5](https://longbridge.com/en/news/297982861.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**